Retatrutide vs. Tirzepatide vs. Semaglutide: A Clinical Comparison

Three generations of GLP-1 class compounds are now available or in late-stage clinical trials. For prescribers offering weight management programs, understanding the differences between semaglutide, tirzepatide, and retatrutide helps you match the right compound to the right patient.

Semaglutide is a selective GLP-1 receptor agonist. Its effects are mediated entirely through GLP-1 receptor activation: appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion, and reduced glucagon.

Tirzepatide adds GIP receptor agonism to GLP-1. GIP enhances insulin secretion and may have direct effects on adipose tissue metabolism. The dual mechanism produces greater weight loss than GLP-1 agonism alone.

Retatrutide adds glucagon receptor agonism to the GLP-1/GIP combination. Glucagon increases energy expenditure and promotes fat oxidation. The triple mechanism is thought to produce the greatest weight loss of the three.

Important caveats:

• These trials enrolled different populations and used different designs — direct comparison is not possible
• The retatrutide data is from a Phase 2 trial; Phase 3 results are pending
• Individual patient responses vary significantly

Semaglutide has the most mature cardiovascular outcomes data. Tirzepatide and retatrutide cardiovascular outcomes trials are ongoing.

All three compounds share the GLP-1 class side effect profile:

• Nausea (most common)
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite

Differences:

• Tirzepatide is generally considered better tolerated than semaglutide at equivalent weight loss doses
• Retatrutide may have a higher incidence of GI side effects due to the glucagon component
• Retatrutide may increase heart rate more than semaglutide or tirzepatide (glucagon receptor effect)

• First-line GLP-1 therapy for most patients
• Patients with established cardiovascular disease (strongest CV outcomes data)
• Patients who prefer a well-established compound with the longest track record
• Cost-sensitive patients (may be more affordable as compounded)

• Patients who need greater weight loss than semaglutide typically produces
• Patients with type 2 diabetes (strongest glycemic efficacy)
• Patients who have not achieved adequate response to semaglutide
• Patients who tolerated semaglutide poorly (tirzepatide may be better tolerated)

• Patients who have not achieved adequate response to tirzepatide
• Patients seeking the most advanced option available
• Patients who understand the compound is not yet FDA-approved
• Practices that want to differentiate their offering

Patients who do not achieve adequate response to one compound can be switched to another. General principles:

• Allow adequate time at the target dose before switching (at least 12 weeks)
• Document the reason for switching
• Start the new compound at the lowest dose and titrate
• Monitor for additive GI side effects during the transition

We supply all three compounds through our 503A portal:

• Semaglutide: Standard catalog, multiple strengths
• Tirzepatide: Standard catalog, full dose range
• Retatrutide: Special order, lyophilized powder, pre-constituted, and wet mix

Request portal access →

This content is for informational and educational purposes only. It does not constitute medical advice. Retatrutide is not FDA-approved. Prescribers should use clinical judgment when selecting therapy.